NSW DRUG AND ALCOHOL CLINICAL RESEARCH AND IMPROVEMENT NETWORK



PRIORITY 1: ESTABLISH, SUPPORT AND GROW THE NETWORK

STRATEGIC OBJECTIVES	ACTIVITIES	MILESTONE TARGETS	ACHIEVEMENTS (2019 - 2021)
1.1 To provide sustainable leadership in clinical research activities in the AOD sector in NSW, in collaboration with clinicians, consumers, professional groups and academic researchers and institutions	Increase network membership Convene Advisory Group	 Effective and efficient network operations Number of NSW multisite clinical research studies increased Research recruitment/accrual rates improved Breadth of clinical research and quality improvement questions and methodologies expanded 	 Strategic Plan 2019-2021 developed, endorsed, and implemented Established Network governance and Terms of Reference Established and maintained a quarterly Council meeting schedule Links formed with National Centre for Clinical Research on Emerging Drugs (NCCRED), Network of Alcohol and other Drug Agencies (NADA) Full membership of the Australian Clinical Trials Alliance (ACTA) achieved
1.2 To promote and facilitate collaboration in inter-disciplinary multisite clinical research and quality improvement activities across AOD services in NSW	Implement systems and processes to enable assessment and scale up of research proposals Facilitate interdisciplinary contributions to AOD clinical research and quality improvement		 Welcomed 4 new member organisations (CCLHD, ISLHD, JHFMHN, NSLHD) Initiated membership conversations with NADA and WNSWLHD Initiated a collaborative project with NADA and the Ministry of Health to conduct a survey of research capacity across the public and NGO AOD sectors Contributed to national strategies including the Special Commission of Inquiry into the Drug Ice Purchased iPads to allocate to and share with member organisations Invested in training and professional development for member organisations, including an ongoing Good Clinical Practice Train the Trainer program Developed DACRIN's visual identity and marketed DACRIN in wide range of forums and conferences Developed operational systems and processes to facilitate scale up of otherwise localised studies Developed process to facilitate discussion and development of collaborative research funding applications Developed a Project Register showcasing the breadth of collaborative clinical research conducted across member services DACRIN's ClinTrial Refer app established, populated, and maintained



PRIORITY 2: DEVELOP CLINICAL RESEARCH INFRASTRUCTURE

STRATEGIC OBJECTIVES	ACTIVITIES	MILESTONE TARGETS	ACHIEVEMENTS (2019 - 2021)
2.1 To streamline AOD clinical research governance, including shared policies and procedures across participating services	Develop shared governance and operations framework for multisite research	Effective and efficient shared governance and operational systems and processes	Consulted in initiatives of the Australian Commission of Safety and Quality in Health Care including the National Clinical Trials Governance Framework
	Establish shared peer review and stakeholder consultation mechanisms	Capacity for independent peer review and stakeholder consultation	 Implemented quarterly DACRIN Coordinator Resource Sharing Days Conducted empirical review of reimbursement practices for AOD research
2.2 To develop common research metrics and databases, enabling pooling of AOD clinical data and facilitating meta-analyses, with particular regard to the mounting importance of clinical informatics and data linkage methodologies	Formulate standardised approaches to clinical research data and data management	Standardised case report forms and comparable data collection across future DACRIN studies	 Initiated DACRIN Data Project with the objective of standardising data collection across AOD clinical research projects
	Enhance shared understanding of access to and use of clinical data for research purposes	Clinical data ownership and access issues documented and disseminated	 Participated in training and education in use of clinical data for research purposes Established relationship with COQI Program Manager and broader COQI team
			Obtained membership of joint COQI/NDARC Pragmatic Trials Special Interest Group which seeks to develop a proof of concept 'faux' trial using routine clinical data

PRIORITY 3: BUILD CLINICAL RESEARCH AND TRANSLATION CAPACITY

STRATEGIC OBJECTIVES	ACTIVITIES	MILESTONE TARGETS	ACHIEVEMENTS (2019 - 2021)
3.1 To increase clinician, consumer and researcher engagement in AOD clinical research and quality improvement activities, including by facilitating workforce development and other capacity building opportunities	Support capacity-building partnerships between clinicians and researchers	 Number of clinicians, consumers and researchers contributing to clinical research increased Clinicians and consumers enabled to pose, review and refine research questions and protocols Clients enabled to consider the personal implications of clinical research Clinical research results implemented in a range of AOD services and settings 	 Supported 47 training or professional development opportunities for staff of 10 LHDs/LHNs Drafted Terms of Reference and application form for DACRIN Professional Development Award for AOD Clinical Research. Drafted a model of collaboration and partnership between consumers, clinicians and researchers as the foundation of AOD clinical research and evaluation activities Developed list of peer reviewed publications. Led or contributed to development or updating of multiple State and national clinical practice guidelines, including for depot buprenorphine, alcohol, take home naloxone, toxicology and toxinology, AOD withdrawal, paracetamol poisoning and opioid safety
	Facilitate clinician and consumer input into research questions and protocols		
3.2 To implement strategies that enable clinician and consumer input into the development of research questions and protocols, and enhance the translation of findings into AOD clinical practice	Implement feedback process to provide research results to participating clinical services and clients Support member organisations to identify and address barriers to translation of research results		